• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

菌株ADS024可保护人结肠上皮细胞免受毒素介导的凋亡。

ADS024, a strain, protects human colonic epithelial cells against toxin-mediated apoptosis.

作者信息

Xie Ying, Chupina Estrada Andrea, Nelson Becca, Feng Hanping, Pothoulakis Charalabos, Chesnel Laurent, Koon Hon Wai

机构信息

Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, United States.

Department of Gastroenterology, The First Hospital of China Medical University, Shenyang, Liaoning, China.

出版信息

Front Microbiol. 2023 Jan 10;13:1072534. doi: 10.3389/fmicb.2022.1072534. eCollection 2022.

DOI:10.3389/fmicb.2022.1072534
PMID:36704560
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9873417/
Abstract

infection (CDI) causes intestinal injury. Toxin A and toxin B cause intestinal injury by inducing colonic epithelial cell apoptosis. ADS024 is a strain in development as a single-strain live biotherapeutic product (SS-LBP) to prevent the recurrence of CDI following the completion of standard antibiotic treatment. We evaluated the protective effects of the sterile filtrate and ethyl acetate extract of conditioned media from ADS024 and DSM7 (control strain) against mucosal epithelial injury in toxin-treated human colonic tissues and apoptosis in toxin-treated human colonic epithelial cells. Ethyl acetate extracts were generated from conditioned culture media from DSM7 and ADS024. Toxin A and toxin B exposure caused epithelial injury in fresh human colonic explants. The sterile filtrate of ADS024, but not DSM7, prevented toxin B-mediated epithelial injury in fresh human colonic explants. Both sterile filtrate and ethyl acetate extract of ADS024 prevented toxin-mediated apoptosis in human colonic epithelial cells. The anti-apoptotic effects of ADS024 filtrate and ethyl acetate extract were dependent on the inhibition of caspase 3 cleavage. The sterile filtrate, but not ethyl acetate extract, of ADS024 partially degraded toxin B. ADS024 inhibits toxin B-mediated apoptosis in human colonic epithelial cells and colonic explants.

摘要

艰难梭菌感染(CDI)会导致肠道损伤。毒素A和毒素B通过诱导结肠上皮细胞凋亡来造成肠道损伤。ADS024是一种正在开发的单一菌株活生物治疗产品(SS-LBP),用于在标准抗生素治疗完成后预防CDI复发。我们评估了ADS024和DSM7(对照菌株)条件培养基的无菌滤液和乙酸乙酯提取物对毒素处理的人结肠组织中黏膜上皮损伤以及毒素处理的人结肠上皮细胞凋亡的保护作用。乙酸乙酯提取物由DSM7和ADS024的条件培养基制备而成。毒素A和毒素B暴露导致新鲜人结肠外植体出现上皮损伤。ADS024的无菌滤液而非DSM7的无菌滤液可预防新鲜人结肠外植体中毒素B介导的上皮损伤。ADS024的无菌滤液和乙酸乙酯提取物均可预防人结肠上皮细胞中毒素介导的凋亡。ADS024滤液和乙酸乙酯提取物的抗凋亡作用依赖于对半胱天冬酶3切割的抑制。ADS024的无菌滤液而非乙酸乙酯提取物可部分降解毒素B。ADS024可抑制毒素B介导的人结肠上皮细胞和结肠外植体凋亡。

相似文献

1
ADS024, a strain, protects human colonic epithelial cells against toxin-mediated apoptosis.菌株ADS024可保护人结肠上皮细胞免受毒素介导的凋亡。
Front Microbiol. 2023 Jan 10;13:1072534. doi: 10.3389/fmicb.2022.1072534. eCollection 2022.
2
ADS024, a single-strain live biotherapeutic product of alleviates dextran sulfate-mediated colitis in mice, protects human colonic epithelial cells against apoptosis, and maintains epithelial barrier function.ADS024是一种单菌株活生物治疗产品,可减轻硫酸葡聚糖介导的小鼠结肠炎,保护人结肠上皮细胞免于凋亡,并维持上皮屏障功能。
Front Microbiol. 2024 Jan 10;14:1284083. doi: 10.3389/fmicb.2023.1284083. eCollection 2023.
3
Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against infection challenge .新型非定殖单菌株活生物治疗产品ADS024可预防感染挑战。
World J Gastrointest Pathophysiol. 2023 Aug 24;14(4):71-85. doi: 10.4291/wjgp.v14.i4.71.
4
Identification of ADS024, a newly characterized strain of Bacillus velezensis with direct Clostridiodes difficile killing and toxin degradation bio-activities.鉴定 ADS024,一种新型的韦氏芽孢杆菌菌株,具有直接杀灭艰难梭菌和降解毒素的生物活性。
Sci Rep. 2022 Jun 3;12(1):9283. doi: 10.1038/s41598-022-13248-4.
5
LPA3 agonist-producing Bacillus velezensis ADS024 is efficacious in multiple neuroinflammatory disease models.产 LPA3 激动剂解淀粉芽孢杆菌 ADS024 在多种神经炎症性疾病模型中有效。
Brain Behav Immun. 2024 Oct;121:384-402. doi: 10.1016/j.bbi.2024.08.024. Epub 2024 Aug 13.
6
Therapeutic Mechanism of Macrophage Inflammatory Protein 1 α Neutralizing Antibody (CCL3) in Clostridium difficile Infection in Mice.巨噬细胞炎症蛋白 1α 中和抗体(CCL3)在小鼠艰难梭菌感染中的治疗机制。
J Infect Dis. 2020 Apr 27;221(10):1623-1635. doi: 10.1093/infdis/jiz640.
7
Effect of Clostridium difficile toxin A on human intestinal epithelial cells: induction of interleukin 8 production and apoptosis after cell detachment.艰难梭菌毒素A对人肠上皮细胞的作用:细胞脱离后白细胞介素8生成及细胞凋亡的诱导
Gut. 1996 Mar;38(3):337-47. doi: 10.1136/gut.38.3.337.
8
Effect of Clostridium difficile toxin A on human colonic lamina propria cells: early loss of macrophages followed by T-cell apoptosis.艰难梭菌毒素A对人结肠固有层细胞的影响:巨噬细胞早期丢失,随后T细胞凋亡。
Infect Immun. 1998 Nov;66(11):5462-9. doi: 10.1128/IAI.66.11.5462-5469.1998.
9
Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa.布拉氏酵母菌蛋白酶可抑制艰难梭菌毒素A和B对人结肠黏膜的作用。
Infect Immun. 1999 Jan;67(1):302-7. doi: 10.1128/IAI.67.1.302-307.1999.
10
Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes.人源单克隆抗体针对艰难梭菌毒素 A 和 B 可抑制毒素在人结肠和外周血单核细胞中的炎症和组织学反应。
Antimicrob Agents Chemother. 2013 Jul;57(7):3214-23. doi: 10.1128/AAC.02633-12. Epub 2013 Apr 29.

引用本文的文献

1
What's New and What's Next in Fecal Microbiota Transplantation?粪便微生物群移植的新进展与未来方向?
Biologics. 2025 Aug 21;19:481-496. doi: 10.2147/BTT.S486372. eCollection 2025.
2
Citrulline Inhibits Clostridioides difficile Infection With Anti-inflammatory Effects.瓜氨酸通过抗炎作用抑制艰难梭菌感染。
Cell Mol Gastroenterol Hepatol. 2025;19(6):101474. doi: 10.1016/j.jcmgh.2025.101474. Epub 2025 Feb 7.
3
Microbiota-Based Live Biotherapeutic Products for Infection- The Devil is in the Details.用于感染治疗的基于微生物群的活体生物治疗产品——细节决定成败。

本文引用的文献

1
Identification of ADS024, a newly characterized strain of Bacillus velezensis with direct Clostridiodes difficile killing and toxin degradation bio-activities.鉴定 ADS024,一种新型的韦氏芽孢杆菌菌株,具有直接杀灭艰难梭菌和降解毒素的生物活性。
Sci Rep. 2022 Jun 3;12(1):9283. doi: 10.1038/s41598-022-13248-4.
2
Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults.美国传染病学会 (IDSA) 和美国医疗保健流行病学学会 (SHEA) 的临床实践指南:2021 年关于成人艰难梭菌感染管理的重点更新指南。
Clin Infect Dis. 2021 Sep 7;73(5):755-757. doi: 10.1093/cid/ciab718.
3
Infect Drug Resist. 2024 Feb 15;17:623-639. doi: 10.2147/IDR.S419243. eCollection 2024.
4
ADS024, a single-strain live biotherapeutic product of alleviates dextran sulfate-mediated colitis in mice, protects human colonic epithelial cells against apoptosis, and maintains epithelial barrier function.ADS024是一种单菌株活生物治疗产品,可减轻硫酸葡聚糖介导的小鼠结肠炎,保护人结肠上皮细胞免于凋亡,并维持上皮屏障功能。
Front Microbiol. 2024 Jan 10;14:1284083. doi: 10.3389/fmicb.2023.1284083. eCollection 2023.
5
Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against infection challenge .新型非定殖单菌株活生物治疗产品ADS024可预防感染挑战。
World J Gastrointest Pathophysiol. 2023 Aug 24;14(4):71-85. doi: 10.4291/wjgp.v14.i4.71.
6
infection: microbe-microbe interactions and live biotherapeutics.感染:微生物-微生物相互作用与活体生物治疗剂
Front Microbiol. 2023 May 9;14:1182612. doi: 10.3389/fmicb.2023.1182612. eCollection 2023.
Detection and characterization of a rare two-component lantibiotic, amyloliquecidin GF610 produced by Bacillus velezensis, using a combination of culture, molecular and bioinformatic analyses.采用培养、分子和生物信息学分析相结合的方法,检测并鉴定了由解淀粉芽孢杆菌 GF610 产生的一种罕见的双组份类细菌素——短小杆菌肽 GF610。
J Appl Microbiol. 2022 Feb;132(2):994-1007. doi: 10.1111/jam.15290. Epub 2021 Sep 15.
4
Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection.复发性艰难梭菌感染粪便微生物群移植随机对照试验的异质性。
Dig Dis Sci. 2022 Jul;67(7):2763-2770. doi: 10.1007/s10620-021-07141-9. Epub 2021 Jul 18.
5
RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients' Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections.RBX7455,一种非冷冻、口服的研究性活体生物治疗药物,在复发性艰难梭菌感染的 1 期研究中安全、有效,并能改变患者的微生物组。
Clin Infect Dis. 2021 Oct 5;73(7):e1613-e1620. doi: 10.1093/cid/ciaa1430.
6
Cell death in the gut epithelium and implications for chronic inflammation.肠道上皮细胞死亡及其对慢性炎症的影响。
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):543-556. doi: 10.1038/s41575-020-0326-4. Epub 2020 Jul 10.
7
Live Biotherapeutic Products, A Road Map for Safety Assessment.活体生物治疗产品,安全性评估路线图。
Front Med (Lausanne). 2020 Jun 19;7:237. doi: 10.3389/fmed.2020.00237. eCollection 2020.
8
Real-world Experience of Bezlotoxumab for Prevention of Infection: A Retrospective Multicenter Cohort Study.贝佐妥单抗预防感染的真实世界经验:一项回顾性多中心队列研究。
Open Forum Infect Dis. 2020 Mar 19;7(4):ofaa097. doi: 10.1093/ofid/ofaa097. eCollection 2020 Apr.
9
Mechanism of Antibacterial Activity of C-1 Lipopeptide toward Anaerobic .C-1 脂肽类抗生素抗厌氧菌的作用机制。
Biomed Res Int. 2020 Mar 3;2020:3104613. doi: 10.1155/2020/3104613. eCollection 2020.
10
Therapeutic Mechanism of Macrophage Inflammatory Protein 1 α Neutralizing Antibody (CCL3) in Clostridium difficile Infection in Mice.巨噬细胞炎症蛋白 1α 中和抗体(CCL3)在小鼠艰难梭菌感染中的治疗机制。
J Infect Dis. 2020 Apr 27;221(10):1623-1635. doi: 10.1093/infdis/jiz640.